BG Medicine Revenues Jump to $622K in Q2; Firm Withdraws CardioScore 510(k) | GenomeWeb

BG Medicine said this week that revenues for the second quarter increased 181 percent year over year, rising to $622,000 from $221,000 a year ago and beating the average Wall Street estimate of $520,000.

Product revenues spiked to $566,000 from $46,000 a year ago, "reflecting increasing demand for the BGM Galectin-3 test," the company said, while service revenues dropped to $56,000 from $175,000.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.